UroGen Pharma Ltd.
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
About UroGen Pharma
Pharmaceutical Preparations, SIC 2834
UroGen Pharma is a biotechnology company focused on developing and commercializing therapeutic solutions for urothelial and specialty cancers. Utilizing its proprietary reverse-thermal hydrogel technology, RTGel, the company creates sustained-release formulations designed to extend drug exposure in the urinary tract. Its approved commercial products include Jelmyto, developed to ablate tumors non-surgically in adult patients with low-grade upper tract urothelial cancer, and Zusduri, designed for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Additionally, the company advances pipeline candidates such as UGN-103, UGN-104, and UGN-501. Its customer base comprises healthcare professionals, physicians, hospitals, and pharmacies treating cancer patients.
The company operates commercially within the United States, supported by a specialized field team of approximately 150 customer-facing personnel who engage with urology and oncology practitioners, care facilities, and key accounts. In addition to commercializing products nationwide across Medicare, Medicaid, and private commercial health plans, the company conducts multicenter clinical trials globally. The provided excerpt does not disclose the location of the company's corporate headquarters.
Summary of the business section of UroGen Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- UroGen Pharma Ltd.
- Headquarters
- Ra'Anana, L3
- Address
- 9 Ha'Ta'Asiya St 4365007
- Phone
- 972 9 770 7601
- Website
- urogen.com
- Employees
- 291, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- URGN
- Exchange
- Nasdaq
- IPO date
- May 5, 2017
- Shares outstanding
- 49M, Jul 28, 2026
- Public float
- $620.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1668243
- CUSIP
- M96088105
- ISIN
- USM960881052
- LEI
- 549300C0YCX7CG2G5D50
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark Schoenberg | Chief Medical Officer | 67,849 |
| Jason Drew Smith | General Counsel | 53,141 |
| Elizabeth A. Barrett | Chief Executive Officer | 313,358 |
| Chris Degnan | Chief Financial Officer | 2,280 |
| James A. Robinson Jr. | Director | 8,000 |
| Daniel George Wildman | Director | 2,000 |
| Leana Wen | Director | 2,000 |
| Cynthia M. Butitta | Director | 2,000 |
| Arie Belldegrun | Director | 408,693 |
| Stuart Holden | Director | 2,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Elizabeth Barrett | $4.31M | $11.84M | $1.18M | $264 | – |
| FY2024 Elizabeth Barrett | $4.15M | $1.94M | $1.23M | $120 | – |
| FY2023 Elizabeth Barrett | $4.64M | $6.32M | $1.43M | $169 | – |
| FY2022 | $1.87M | $1.77M | $832.07K | $93 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of January 31, 2026, we had 291 employees worldwide, 251 in the United States and 40 in Israel, many of whom hold advanced degrees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 10, 2020 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 5, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| May 1, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |